Vismodegib (Erivedge) for advanced basal cell carcinoma

P and T

Volumn 37, Issue 12, 2012, Pages 670-682

  Fellner, Chris ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; AZITHROMYCIN; CARBAMAZEPINE; CLARITHROMYCIN; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; MODAFINIL; NORETHISTERONE; PHENOBARBITAL; PROTON PUMP INHIBITOR; ROSIGLITAZONE; VISMODEGIB;

AGEUSIA; ALOPECIA; AMENORRHEA; ARTHRALGIA; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DYSGEUSIA; FATIGUE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOKALEMIA; HYPONATREMIA; MULTICENTER STUDY (TOPIC); MUSCLE SPASM; NAUSEA; NONHUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; UREMIA; VOMITING; WEIGHT REDUCTION;

EID: 84872041487     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (57)

1. Jacob A. Observations respecting an ulcer of peculiar character, which attacks the eyelids and other parts of the face. Dublin Hosp Rep Commun Med Surg 1827;4:232-239.
2. Miller SJ. Biology of basal cell carcinoma (part I). J Am Acad Dermatol 1991;24:1-13.
3. Miller SJ. Biology of basal cell carcinoma (part II). J Am Acad Dermatol 1991;24:161-175.
4. Miller SJ. Aetiology and pathogenesis of basal cell carcinoma. Clin Dermatol 1995;13:527-536.
5. Lacour JP. Carcinogenesis of basal cell carcinomas: Genetics and molecular mechanisms. Br J Dermatol 2002;146(Suppl 61):17-19.
6. American Cancer Society. Skin cancer: Basal and squamous cell. January 31, 2012. Available at: http://documents. cancer.org/acs/groups/cid/documents/ webcontent/003139-pdf.pdf. Accessed February 22, 2012.
7. Skin Cancer Foundation. Skin cancer facts. Available at: www.skincancer.org/ skin-cancer-information/skin-cancerfacts. Accessed February 27, 2012.
8. Lewis WH, ed. Gray's Anatomy of the Human Body, 20th ed. Philadelphia: Lea & Febiger, 1918.
9. McGrath JA, Eady RAJ, Pope FM. Anatomy and organization of human skin. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook's Textbook of Dermatology, 7th ed, Oxford, U.K.: Blackwell Science Ltd; 2004:3.1-3.84.
10. Williams AC. Structure and function of skin. In: Transdermal and Topical Drug Delivery: From Theory to Clinical Practice. London, U.K.: Pharmaceutical Press; 2004:1-25.
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Basal cell and squamous cell skin cancers, Version 1.2012. Available at: www.nccn.org/ professionals/physician_gls/pdf/nmsc. pdf. Accessed February 27, 2012.
12. Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol 2007;8:462-469.
13. Walling HW, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma: Presentation, pathogenesis, and management. Cancer Metastasis Rev 2004;23:389-402.
14. American Academy of Dermatology. Skin cancer: Who gets and causes. 2012. Available at: www.aad.org/skin-conditions/ dermatology-a-to-z/skin-cancer/whogets-causes. Accessed February 27, 2012.
15. Stulberg DL, Crandell B, Fawcett RS. Diagnosis and treatment of basal cell and squamous cell carcinoma. Am Fam Physician 2004;70:1481-1488.
16. Lear JT, Smith AG. Basal cell carcinoma. Postgrad Med J 1997;73:538-542.
17. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005;353:2262-2269.
18. National Cancer Institute, Surveillance Epidemiology and End Results (SEER). SEER stat fact sheets: Other non-epithelial skin. Available at: http://seer.cancer.gov/ statfacts/html/othskin.html. Accessed February 28, 2012
19. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003;327:794-798.
20. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: Incidence. J Am Acad Dermatol 1994;30:774-778.
21. Holmes SA, Malinovszky K, Roberts DL. Changing trends in non-melanoma skin cancer in South Wales, 1988-1998. Br J Dermatol 2000;143:1224-1229.
22. Marks R, Staples M, Giles G. Trends in non-melanocytic skin cancer treated in Australia: The second national survey. Int J Cancer 1993;53:585-590.
23. de Vries E, Louwman M, Bastiaens M, et al. Rapid and continuous increases in incidence rates of basal cell carcinoma in the southeast Netherlands since 1973. J Invest Dermatol 2004;123:634-638.
24. Strayer SM, Reynolds PL. Diagnosing skin malignancy: Assessment of predictive clinical criteria and risk factors. J Fam Pract 2003;52:210-218.
25. Crowson AN. Basal cell carcinoma: Biology, morphology, and clinical implications. Modern Pathol 2006;19:S127-S149.
26. Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004: A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006;55:490-500.
27. National Cancer Institute. Basal cell carcinoma of the skin: Treatment. July 29, 2011. Available at: www.cancer.gov/ cancer topics/pdq/treatment/skin/ HealthProfessional. Accessed February 27, 2012.
28. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008;159:35-48.
29. Samarasinghe V, Madan V, Lear JT. Focus on basal cell carcinoma. J Skin Cancer 2011;2011:328615 (online).
30. Wadhera A, Fazio M, Bricca G, Stanton O. Metastatic basal cell carcinoma: A case report and literature review. How accurate is our incidence data? Dermatol Online J 2006;12(5):7.
31. Raszewski RL, Guyuron B. Long-term survival following nodal metastases from basal cell carcinoma. Ann Plast Surg 1990;24:170-175.
32. FDA approves new treatment for most common type of skin cancer, January 30, 2012. Available at: www.fda.gov/News Events/Newsroom/PressAnnouncements/ ucm289545.htm. Accessed February 28, 2012.
33. Erivedg (vismodegib), prescribing information. South San Francisco, Calif.: Genentech; January 2012. Available at: www. gene.com/gene/products/information/ erivedge/pdf/erivedge_prescribing.pdf. Accessed February 22, 2012.
34. Prous Science. Molecule of the month: Vismodegib. February 16, 2012. Available at: www.prous.com/molecules/default. asp?ID=210. Accessed February 28, 2012.
35. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2001;2:172-180.
36. Ahn S, Joyner AL. In vivo analysis of quiescent adult neural stem cells responding to Sonic Hedgehog. Nature 2005;437:894-897.
37. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate selfrenewal of normal and malignant human mammary stem cells. Cancer Res 2006;66:6063-6071.
38. McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of Hedgehog signaling. Curr Top Dev Biol 2003;53:1-114.
39. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-1172.
40. Daya-Grosjean L, Couvé-Privat S. Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett 2005;225:181-192.
41. Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009;30:303-312.
42. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-1178.
43. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006;5:1026-1033.
44. Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90-92.
45. Epstein EH. Basal cell carcinoma: Attack of the Hedgehog. Nat Rev Cancer 2008;8:743-754.
46. Graham RA, Hop CECA, Lum BL, et al. Single and multiple-dose IV and oral pharmacokinetics of the Hedgehog pathway inhibitor vismodegib (GDC-0449) during a phase 1 study in healthy female subjects. Poster, American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; Dallas, March 2-5, 2011. Available at: www.xceleron.com. Accessed March 1, 2012.
47. Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: The role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2011;17:2512-2520.
48. LoRusso PM, Piha-Paul SA, Colevas AD, et al. Pharmacokinetic assessment of drug-drug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors (Abstract No. B188). Mol Cancer Ther 2011;10(Suppl 1).
49. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-2511.
50. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171-2179.
51. FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma. Roche, January 30, 2012. Available at: www. roche.com/media/media_releases/medcor-2012-01-30.htm. Accessed February 29, 2012.
52. Vismodegib Briefing Package: Pediatric ODAC Committee Meeting. South San Francisco, Calif.: Genentech; November 1, 2011. Available at: www.fda. gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/ UCM277585.pdf. Accessed February 29, 2012.
53. FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer. Roche Group, November 9, 2011. Available at: www.roche.com/media/ media_releases/med-cor-2011-11-09. htm. Accessed March 5, 2011.
54. FDA grants priority review for vismodegib for advanced skin cancer. Oncology Times 2011;33(23):5.
55. Grogan K. FDA approves Roche's skin cancer drug Erivedge. Pharma Times Online, January 31, 2012. Available at: www.pharmatimes.com/article/12-01-31/ FDA_approves_Roche_s_skin_cancer_ drug_Erivedge.aspx. Accessed February 29, 2012.
56. Corbett Dooren J, Winslow R. New type of cancer drug gets approval. The Wall Street Journal January 31, 2012 (online). Available at: http://online.wsj.com. Accessed February 29, 2012.
57. Access, coverage, and patient assistance for Erivedge (vismodegib) capsule. Genentech, 2012. Available at: www.erivedge. com. Accessed March 5, 2012.